Spark Therapeutics' Luxturna does not meet ICER cost-effectiveness standards
The Institute for Clinical and Economic Review, or ICER, released its revised evidence report assessing the comparative clinical effectiveness and value of Luxturna, Spark Therapeutics for treatment of vision loss associated with biallelic RPE65-mediated retinal disease. This evidence report will be the subject of an upcoming public meeting of the Midwest Comparative Effectiveness Public Advisory Council, or CEPAC, on January 25. The Midwest CEPAC is one of ICER's three independent evidence appraisal committees. Evidence on Luxturna provides high certainty of at least a small net health benefit for patients with biallelic RPE65-mediated retinal disease; however, significant uncertainty remains about the long-term effects and durability of the response to treatment. Assuming a 10-20 year benefit of treatment for 15-year-olds, the average age of patients in the clinical trials, economic analyses found that at the current price of $850,000, use of the treatment would exceed common cost-effectiveness thresholds.